A phase I trial of chemoimmunotherapy combining bacillus Calmette-Guerin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade nonmuscle-invasive bladder cancer.

Manuel R. De Jesus Escano,Daniel Sjöberg,Melissa McCarter,Marlena McGill,Alvin C. Goh,Timothy F. Donahue,S. Machele Donat,Eugene K. Cha,Harry W. Herr,Anoop M. Meraney,Hikmat Al-Ahmadie,David B. Solit,Guido Dalbagni,Dean F. Bajorin,Bernard H. Bochner,Eugene J. Pietzak

A phase I trial of chemoimmunotherapy combining bacillus Calmette-Guerin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade nonmuscle-invasive bladder cancer.

2021

Manuel R. De Jesus Escano
Daniel Sjöberg
Melissa McCarter
Marlena McGill
Alvin C. Goh
Timothy F. Donahue
S. Machele Donat
Eugene K. Cha
Harry W. Herr
Anoop M. Meraney
Hikmat Al-Ahmadie
David B. Solit
Guido Dalbagni
Dean F. Bajorin
Bernard H. Bochner
Eugene J. Pietzak

TPS509Background: Intravesical BCG is the most effective treatment for high-grade non-muscle invasive bladder cancer (NMIBC), yet recurrences are common. Patients with BCG-relapsing NMIBC are often...

Keywords:

Gemcitabine
Urology
Intravesical bcg
effective treatment
Chemoimmunotherapy
Bladder cancer
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations